220 related articles for article (PubMed ID: 34276005)
21. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
Albert NM; Swindle JP; Buysman EK; Chang C
J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
[TBL] [Abstract][Full Text] [Related]
22. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
Xie W; Zheng F; Song X; Zhong B; Yan L
Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
[TBL] [Abstract][Full Text] [Related]
23. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.
Güder G; Störk S; Gelbrich G; Brenner S; Deubner N; Morbach C; Wallenborn J; Berliner D; Ertl G; Angermann CE
Eur J Heart Fail; 2015 Apr; 17(4):442-52. PubMed ID: 25727879
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the incidence and baseline predictors of the left ventricular ejection fraction returning to normal after dilated cardiomyopathy in postmenopausal women: a retrospective, observational study.
Yuan X; Mao S; Tang Q
J Int Med Res; 2020 May; 48(5):300060520922471. PubMed ID: 32429729
[TBL] [Abstract][Full Text] [Related]
25. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Heart Failure With Chronic Kidney Disease - Propensity Score Matching Analysis.
Kim HJ; Lee MH; Jo SH; Seo WW; Kim SE; Kim KJ; Choi JO; Ahn HS; Choi DJ; Ryu KH
Circ J; 2019 Dec; 84(1):83-90. PubMed ID: 31776309
[TBL] [Abstract][Full Text] [Related]
26. Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report.
Brinkley DM; Wang L; Yu C; Grandin EW; Kiernan MS
J Heart Lung Transplant; 2021 Dec; 40(12):1605-1613. PubMed ID: 34663529
[TBL] [Abstract][Full Text] [Related]
27. Absence of left bundle branch block and blood urea nitrogen predict improvement in left ventricular ejection fraction in patients with cardiomyopathy and wearable cardioverter defibrillators.
Mehta NA; Abdulsalam N; Kouides R; Ahmed H; Atif R; Shah A; Taylor S; Chuprun D; Huang D; Rao M
Clin Cardiol; 2020 Mar; 43(3):260-266. PubMed ID: 31860745
[TBL] [Abstract][Full Text] [Related]
28. A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure patients age ≥ 65 years.
Zhang Y; Fonarow GC; Sanders PW; Farahmand F; Allman RM; Aban IB; Love TE; Levesque R; Kilgore ML; Ahmed A
Am J Cardiol; 2011 Nov; 108(10):1443-8. PubMed ID: 21890091
[TBL] [Abstract][Full Text] [Related]
29. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
30. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Impact of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Recurrent Ventricular Tachyarrhythmias and Implantable Cardioverter-Defibrillator Therapies.
Schupp T; Behnes M; Weiß C; Nienaber C; Lang S; Reiser L; Bollow A; Taton G; Reichelt T; Ellguth D; Engelke N; Bertsch T; Akin M; Mashayekhi K; Borggrefe M; Akin I
J Cardiovasc Pharmacol; 2019 May; 73(5):272-281. PubMed ID: 30747784
[TBL] [Abstract][Full Text] [Related]
32. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study).
AlJaroudi WA; Refaat MM; Habib RH; Al-Shaar L; Singh M; Gutmann R; Bloom HL; Dudley SC; Ellinor PT; Saba SF; Shalaby AA; Weiss R; McNamara DM; Halder I; London B;
Am J Cardiol; 2015 Apr; 115(7):924-31. PubMed ID: 25682436
[TBL] [Abstract][Full Text] [Related]
33. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention.
Byun JK; Choi BG; Rha SW; Choi SY; Jeong MH;
Atherosclerosis; 2018 Oct; 277():130-135. PubMed ID: 30212681
[TBL] [Abstract][Full Text] [Related]
34. Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.
Sanam K; Bhatia V; Bajaj NS; Gaba S; Morgan CJ; Fonarow GC; Butler J; Deedwania P; Prabhu SD; Wu WC; White M; Love TE; Aronow WS; Fletcher RD; Allman RM; Ahmed A
Am J Med; 2016 Oct; 129(10):1067-73. PubMed ID: 27262781
[TBL] [Abstract][Full Text] [Related]
35. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study.
Hsieh YC; Hung CY; Li CH; Liao YC; Huang JL; Lin CH; Wu TJ
Medicine (Baltimore); 2016 May; 95(20):e3721. PubMed ID: 27196491
[TBL] [Abstract][Full Text] [Related]
37. Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veterans' Health Administrative Database.
Mathew RO; Lo KB; Tipparaju P; Phelps E; Sidhu MS; Bangalore S; Herzog C; Vaduganathan M; Tang WHW; Rangaswami J
Cardiorenal Med; 2021; 11(5-6):226-236. PubMed ID: 34601469
[TBL] [Abstract][Full Text] [Related]
38. Timing of prescription of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients hospitalized for acute heart failure with reduced/mildly reduced ejection fraction: a retrospective analysis.
Ishii T; Matsue Y; Matsunaga Y; Iekushi K; Homma Y; Morita Y
Heart Vessels; 2024 Jan; 39(1):25-34. PubMed ID: 37695543
[TBL] [Abstract][Full Text] [Related]
39. Doses of renin-angiotensin system inhibitors but not beta-blockers predict outcome after ST-elevation myocardial infarction.
Liu PY; Chen CL; Yu MC; Ko YL; Hsu SY; Chou HH; Yeh KH; Duan DM; Chen MH; Lin JF
Acta Clin Belg; 2019 Oct; 74(5):334-341. PubMed ID: 30295167
[No Abstract] [Full Text] [Related]
40. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
